Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H6O24P6.9Na.3H |
Molecular Weight | 857.8718 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[H+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)O[C@@H]1[C@H](OP([O-])([O-])=O)[C@H](OP([O-])([O-])=O)[C@@H](OP([O-])([O-])=O)[C@H](OP([O-])([O-])=O)[C@H]1OP([O-])([O-])=O
InChI
InChIKey=FENRSEGZMITUEF-ATTCVCFYSA-E
InChI=1S/C6H18O24P6.9Na/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15;;;;;;;;;/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24);;;;;;;;;/q;9*+1/p-9/t1-,2-,3-,4+,5-,6-;;;;;;;;;
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H6O24P6 |
Molecular Weight | 647.94 |
Charge | -12 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8777015https://www.ncbi.nlm.nih.gov/pubmed/27272247Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16401188 | https://www.ncbi.nlm.nih.gov/pubmed/28233043 | https://www.ncbi.nlm.nih.gov/pubmed/26859648 | https://www.ncbi.nlm.nih.gov/pubmed/20127021
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8777015https://www.ncbi.nlm.nih.gov/pubmed/27272247
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16401188 | https://www.ncbi.nlm.nih.gov/pubmed/28233043 | https://www.ncbi.nlm.nih.gov/pubmed/26859648 | https://www.ncbi.nlm.nih.gov/pubmed/20127021
Phytate Sodium is a complex sodium salt of the corn-derived plant component Phytic Acid , that used as a chelating agent in all types of cosmetic products, including soaps, shampoos, balms and leave-on products for the face or body. Phytate Sodium is a biodegradable product and appears in the form of a dark-coloured liquid, is soluble in water and has a characteristic odour. It can be used in all types of cosmetic products, including soaps, shampoos, balms and leave-on products for the face or body. In vivo and in vitro experiments have demonstrated striking anticancer (preventive as well as therapeutic) effects of phytic acid. Research shows anti-carcinogenic effects, albeit to a lesser extent and it acts in inhibiting cancer. In addition to reduction in cell proliferation, phytic acid increases differentiation of malignant cells often resulting in reversion to the normal phenotype. Phytates participation in important intracellular biochemical pathways, normal physiological presence in human cells, tissues, plasma, urine, etc., the levels of which fluctuate with intake, epidemiological correlates of phytate deficiency with disease and reversal of those conditions by adequate intake, and safety – all strongly suggest for phytates inclusion as an essential nutrient, perhaps a vitamin. Phytic acid, mostly as Phytate Sodium or other phytates, is found within the hulls of nuts, seeds, and grains. No detectable phytate (less than 0.02 % of wet weight) was observed in vegetables such as scallion and cabbage leaves or in fruits such as apples, oranges, bananas, or pears. In-home food preparation techniques can break down the phytic acid in all of these foods. Simply cooking the food will reduce the phytic acid to some degree. More effective methods are soaking in an acid medium, sprouting and lactic acid fermentation such as in sourdough and pickling.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0034440 |
|||
Target ID: Metals (Iron, Zinc) |
|||
Target ID: AP2 complex |
|||
Target ID: CHEMBL2363056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28233043 |
|||
Target ID: CHEMBL2364030 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28233043 |
|||
Target ID: GO:0055065 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28233043 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Sources: DOI: 10.1046/j.1365-2621.2002.00620.x |
Preventing | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.nutrientsreview.com/phytonutrients/phytic-acid-inositol-hexaphosphate.html https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=381 https://naturellecosmetics.com/iblog/reasons-for-phytic-acid-use-in-natural-cosmetics http://www.biosiltech.com/pdf/Phytic%20Acid%20Extreme%20-%20Data%20Sheet%202017.pdf http://www.biosiltech.com/pdf/new_formula_sheets/Phytic%20Acid%20Resurfacing%20Toner%20PS1-301.pdf |
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.12 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11673644/ |
1400 mg single, oral dose: 1400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FYTIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.52 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11673644/ |
1400 mg single, oral dose: 1400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FYTIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11673644/ |
1400 mg single, oral dose: 1400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FYTIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/29282978/ Page: 26.0 |
likely |
PubMed
Title | Date | PubMed |
---|---|---|
Development, acceptability and nutritional evaluation of 'Doli Ki Roti'--an indigenously fermented bread. | 2001 |
|
Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans. | 2001 |
|
Sentinel lymph node biopsy in breast cancer: an overview of the Japanese experience. | 2001 |
|
Soybeans and cancer prevention: a complex food and a complex disease. | 2001 |
|
Increased erythritol production in fed-batch cultures of Torula sp. by controlling glucose concentration. | 2001 Apr |
|
Effect of soaking, germination, autoclaving and cooking on chemical and biological value of guar compared with faba bean. | 2001 Aug |
|
In vitro availability of zinc from infant foods with increasing phytic acid contents. | 2001 Aug |
|
Phytate levels in diverse rat tissues: influence of dietary phytate. | 2001 Aug |
|
A novel phytase with sequence similarity to purple acid phosphatases is expressed in cotyledons of germinating soybean seedlings. | 2001 Aug |
|
Inositol hexakisphosphate increases L-type Ca2+ channel activity by stimulation of adenylyl cyclase. | 2001 Aug |
|
Pigs expressing salivary phytase produce low-phosphorus manure. | 2001 Aug |
|
Study on concretions developed around urinary catheters and mechanisms of renal calculi development. | 2001 Aug |
|
GRAB: a physiologic guanine nucleotide exchange factor for Rab3A, which interacts with inositol hexakisphosphate kinase. | 2001 Aug 16 |
|
Effect of myo-inositol(1,4,5)trisphosphate on the hydrolysis of phytic acid by phytase. | 2001 Feb-Apr |
|
[Phytin efficacy in correction of the impaired detoxication liver function in the long-term compression syndrome in rats in prepubertal period]. | 2001 Jan-Feb |
|
Inositol hexaphosphate inhibits ultraviolet B-induced signal transduction. | 2001 Jul |
|
Nutritional composition of uncommon foods and their role in meeting micronutrient needs. | 2001 Jul |
|
Effect of several germination conditions on total P, phytate P, phytase, and acid phosphatase activities and inositol phosphate esters in rye and barley. | 2001 Jul |
|
G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). | 2001 Jul-Aug |
|
[New strains of soil bacilli which mineralize organic phosphorus compounds]. | 2001 Jul-Aug |
|
Proposed phytic acid standard including a method for its analysis. | 2001 Jul-Aug |
|
Accessory spleen in the pelvis diagnosed by Tc-99m phytate scintigraphy. | 2001 Jun |
|
Development and sensory evaluation of soy milk based yoghurt. | 2001 Mar |
|
Purification and properties of extracellular phytase from Bacillus sp. KHU-10. | 2001 May |
|
Dietary diversification/modification strategies to enhance micronutrient content and bioavailability of diets in developing countries. | 2001 May |
|
Biotechnological development of effective phytases for mineral nutrition and environmental protection. | 2001 Nov |
|
Bioavailability of cadmium from infant diets in newborn rats. | 2001 Nov |
|
Oxidation of polyphenols in phytate-reduced high-tannin cereals: effect on different phenolic groups and on in vitro accessible iron. | 2001 Nov |
|
Use of fungal phytase to improve breadmaking performance of whole wheat bread. | 2001 Nov |
|
The use of 99mTc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases. | 2001 Nov |
|
High and low oxygen affinity conformations of T state hemoglobin. | 2001 Nov |
|
The role of hepatobiliary scintigraphy in the follow-up of benign liver tumors secondary to oral contraceptive use. | 2001 Nov |
|
Micronutrient composition and nutritional importance of gathered vegetables in Vietnam. | 2001 Nov |
|
Protective effect of phytic acid on oxidative DNA damage with reference to cancer chemoprevention. | 2001 Nov 2 |
|
High affinity association of myo-inositol trisphosphates with phytase and its effect upon the catalytic potential of the enzyme. | 2001 Nov 23 |
|
Effects of wheat maturation stage and cooking method on dietary fiber and phytic acid contents of firik, a wheat-based local food. | 2001 Oct |
|
Can dietary treatment of non-anemic iron deficiency improve iron status? | 2001 Oct |
|
Complementary feeding practices and dietary intakes from complementary foods amongst weanlings in rural Malawi. | 2001 Oct |
|
Molecular dynamics analysis of a second phosphate site in the hemoglobins of the seabird, south polar skua. Is there a site-site migratory mechanism along the central cavity? | 2001 Oct |
|
Organic phosphates as a new class of soluble guanylate cyclase inhibitors. | 2001 Oct 19 |
|
Identification and characterization of a novel inositol hexakisphosphate kinase. | 2001 Oct 19 |
|
Probing the importance of the amino-terminal sequence of the beta- and gamma-chains to the properties of normal adult and fetal hemoglobins. | 2001 Oct 9 |
|
The response of broilers to the feeding of mash or pelleted diets containing maize of varying particle sizes. | 2001 Sep |
|
Enzyme mechanism and catalytic property of beta propeller phytase. | 2001 Sep |
|
Calcium-binding capacities of different brans under simulated gastrointestinal pH conditions. In vitro study with (45)Ca. | 2001 Sep |
|
Effects of phytic acid and xanthotoxin on growth and detoxification in caterpillars. | 2001 Sep |
|
Processing of newly released ricebean and fababean cultivars: changes in total and available calcium, iron and phosphorus. | 2001 Sep |
|
[In vitro availability of minerals in infant foods with different protein source]. | 2001 Sep-Oct |
|
Enzymatic characterization of organic phosphorus in animal manure. | 2001 Sep-Oct |
|
Preparation of phytate-removed deamidated soybean globulins by ion exchangers and characterization of their calcium-binding ability. | 2002 Jan 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02081287
2,000 - 3,000 mg per day (in two doses)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20930278
In MC65 cells, 48-72-hour treatment with phytic acid (100 uM) provided complete protection against amyloid precursor protein-C-terminal fragment-induced cytotoxicity by attenuating levels of increased intracellular calcium, hydrogen peroxide, superoxide, Aβ oligomers, and moderately upregulated the expression of autophagy (beclin-1) protein.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:29:35 UTC 2023
by
admin
on
Wed Jul 05 22:29:35 UTC 2023
|
Record UNII |
88496G1ERL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C360
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60992770
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
SUB15319MIG
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
9903
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | RxNorm | ||
|
C87690
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
88496G1ERL
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
M8769
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | Merck Index | ||
|
7205-52-9
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
100000159723
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
88496G1ERL
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY | |||
|
CHEMBL2005481
Created by
admin on Wed Jul 05 22:29:35 UTC 2023 , Edited by admin on Wed Jul 05 22:29:35 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |